Pulse Biosciences

The nPulse Vybrance Percutaneous Electrode System (Percutaneous Electrode) is not indicated for use in cardiac procedures. The nPulse Vybrance Percutaneous Electrode System is FDA Cleared for use in the US. FDA 510(k) clearance: K233705, K240782.

Indications for Use: The nPulse Vybrance Percutaneous Electrode System is indicated for ablation of soft tissue in percutaneous, and intraoperative surgical procedures.

"I didn't want to be on medication the rest of my life." Learn why Astra and her doctor chose a nonsurgical option for benign nodules, and discover the groundbreaking tech behind Nanosecond Pulsed Field Ablation (nsPFA™) energy, now known as nPulse™ Vybrance™ technology: ow.ly/oNGH50Y0nvY

During #ThyroidAwarenessMonth and throughout the year, Pulse Biosciences strives to support those affected by thyroid-related diseases and thyroid cancer. Join us in recognizing the strength and resilience of those affected and their loved ones.

The nPulse Vybrance Percutaneous Electrode System (Percutaneous Electrode) is not indicated for use in cardiac procedures. The nPulse Vybrance Percutaneous Electrode System is FDA Cleared for use in the US. FDA 510(k) clearance: K233705, K240782.

Indications for Use: The nPulse Vybrance Percutaneous Electrode System is indicated for ablation of soft tissue in percutaneous, and intraoperative surgical procedures.

DYK? nPulse™ technology non-thermally eliminates cells while sparing collagen, extracellular matrix, and other adjacent non-cellular tissue through Nanosecond Pulsed Field Ablation (nsPFA™) energy. Learn more at our website: ow.ly/VJxc50XNQqi

We’ve demonstrated the amazing power of nanosecond pulsed field ablation (nsPFA™), now with a new name: nPulse™ Vybrance™. More than a name update, this change shows our commitment to paving the way for more groundbreaking advancements that will benefit practices and patients.

Our team was honored to attend the American Thyroid Association (@AmThyroidAssn) Annual Meeting! We met many attendees at our booth and our Expo Theater presentation to discuss Nanosecond Pulsed Field Ablation (nsPFA™) technology and hope to meet even more of you next year.

Thank you to everyone who joined our Expo Theater presentation at the American Thyroid Association (@AmThyroidAssn) Annual Meeting, where we discussed Nanosecond Pulsed Field Ablation (nsPFA™) technology. For attendees, there’s still time to find us at booth 315 to learn more!

Join us today at #atathyroid2025! Our team will be sharing more information at booth 315, and we’re looking forward to meeting with attendees. For those unable to attend, our website can answer questions you may have about nsPFA™ technology.

Our team is looking forward to attending the American Thyroid Association (@AmThyroidAssn) Annual Meeting in Scottsdale, Arizona next week. We hope to meet many of you at booth 315 and at our Expo Theater presentation on September 13. #atathyroid2025

Our team will be delivering an Expo Theater Presentation on Nanosecond Pulsed Field Ablation (nsPFA) technology during the American Thyroid Association (@AmThyroidAssn) Annual Meeting. We also look forward to meeting many of you at booth 315. #atathyroid2025

Pulse Biosciences will host a conference call tomorrow to report business and financial updates for the second quarter of 2025.

Thank you to everyone who joined us at #HRS2025 in San Diego! Watch our live case below highlighting the nsPFA 360˚ Catheter’s ability to rapidly isolate the pulmonary veins with a fast, efficient workflow. We’re grateful to the Na Homolce Hospital team and Dr. Vivek Reddy, Dr. Petr Neuzil and Dr. Gregory Michaud for their collaboration and expertise on this case. Congratulations to Dr. Jan Petru and Dr. Moritoshi Funasako for a great live case: vimeo.com/1086559629 #EPeeps #nsPFA #PulseBiosciences CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.

Congratulations to Dr. Thomas J. Fahey on successfully completing his first cases using Nanosecond Pulsed Field Ablation (nsPFA™) technology — and a big shout out to the entire team at Weill Cornell Medicine! We’re incredibly grateful for your partnership and dedication to advancing patient care. These cases also mark an exciting milestone: 100 “minimally invasive” nsPFA™ cases completed in the U.S.! We’re thrilled to celebrate this achievement with you and look forward to what’s ahead! #Healthcare #nsPFA #WeillCornellMedicine #PatientFirst

Thanks for joining us at #AAES2025! It was great to connect & explore the future of nsPFA™ technology. Missed us? We hope to see you next time! Learn more at pulsebiosciences.com. #nsPFA #PulseBiosciences

Congratulations to Dr. Emad Kandil and the Tulane Surgery team for being the first to treat patients in a hospital OR using Nanosecond Pulsed Field Ablation (nsPFA™) technology. Three procedures in one day at Lakeside LCMC Hospital! #Innovation #Healthcare  #nsPFA #TulaneSurgery #PatientFirst